Programme developing TH 302 (evofosfamide) for advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma cancelled- Merck KGaA/Threshold Pharma

Merck KGaA has announced that it is not planning to file for approval of TH 302 (evofosfamide) in advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma. The decision was made in light of results from two Phase III studies of evofosfamide in combination with chemotherapy in these two types of cancer, as reported by Threshold Pharmaceuticals. Details of the two Phase III studies will be shared with the scientific community once the data have been further analyzed.